Morgan Stanley Upgrades West Pharmaceutical Servs to Overweight, Raises Price Target to $400

Benzinga Newsdesk www.benzinga.com Positive 88.7%

Neg 0% Neu 0% Pos 88.7%

Morgan Stanley analyst Kallum Titchmarsh upgrades West Pharmaceutical Servs (NYSE:WST) from Equal-Weight to Overweight and raises the price target from $365 to $400.